161 related articles for article (PubMed ID: 32376390)
1. MLL-rearranged infant leukaemia: A 'thorn in the side' of a remarkable success story.
Rice S; Roy A
Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194564. PubMed ID: 32376390
[TBL] [Abstract][Full Text] [Related]
2. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
Stumpel DJ; Schneider P; Pieters R; Stam RW
Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale.
Stumpel DJ; Schotte D; Lange-Turenhout EA; Schneider P; Seslija L; de Menezes RX; Marquez VE; Pieters R; den Boer ML; Stam RW
Leukemia; 2011 Mar; 25(3):429-39. PubMed ID: 21116279
[TBL] [Abstract][Full Text] [Related]
4. The role of RAS mutations in MLL-rearranged leukaemia: A path to intervention?
Mansur MB; Ford AM; Emerenciano M
Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):521-526. PubMed ID: 29056538
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.
Schafer E; Irizarry R; Negi S; McIntyre E; Small D; Figueroa ME; Melnick A; Brown P
Blood; 2010 Jun; 115(23):4798-809. PubMed ID: 20215641
[TBL] [Abstract][Full Text] [Related]
6. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Passier MM; Janka-Schaub GE; Sallan SE; Armstrong SA; Pieters R
Leukemia; 2006 Feb; 20(2):264-71. PubMed ID: 16357833
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
Chijimatsu I; Imanaka Y; Tomizawa D; Eguchi M; Nishimura S; Karakawa S; Miki M; Hamamoto K; Fujita N
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28675638
[TBL] [Abstract][Full Text] [Related]
8. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.
Stumpel DJ; Schneider P; van Roon EH; Boer JM; de Lorenzo P; Valsecchi MG; de Menezes RX; Pieters R; Stam RW
Blood; 2009 Dec; 114(27):5490-8. PubMed ID: 19855078
[TBL] [Abstract][Full Text] [Related]
9. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
[TBL] [Abstract][Full Text] [Related]
10. A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program.
Rice S; Jackson T; Crump NT; Fordham N; Elliott N; O'Byrne S; Fanego MDML; Addy D; Crabb T; Dryden C; Inglott S; Ladon D; Wright G; Bartram J; Ancliff P; Mead AJ; Halsey C; Roberts I; Milne TA; Roy A
Nat Commun; 2021 Nov; 12(1):6905. PubMed ID: 34824279
[TBL] [Abstract][Full Text] [Related]
11. A distinct set of long non-coding RNAs in childhood MLL-rearranged acute lymphoblastic leukemia: biology and epigenetic target.
Fang K; Han BW; Chen ZH; Lin KY; Zeng CW; Li XJ; Li JH; Luo XQ; Chen YQ
Hum Mol Genet; 2014 Jun; 23(12):3278-88. PubMed ID: 24488769
[TBL] [Abstract][Full Text] [Related]
12. MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.
Sison EA; Rau RE; McIntyre E; Li L; Small D; Brown P
Br J Haematol; 2013 Mar; 160(6):785-97. PubMed ID: 23294096
[TBL] [Abstract][Full Text] [Related]
13. Absence of global hypomethylation in promoter hypermethylated Mixed Lineage Leukaemia-rearranged infant acute lymphoblastic leukaemia.
Stumpel DJ; Schneider P; van Roon EH; Pieters R; Stam RW
Eur J Cancer; 2013 Jan; 49(1):175-84. PubMed ID: 22921182
[TBL] [Abstract][Full Text] [Related]
14. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
[TBL] [Abstract][Full Text] [Related]
15. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
[TBL] [Abstract][Full Text] [Related]
16. Relatively favorable prognosis for MLL-rearranged childhood acute leukemia with reciprocal translocations.
Yang L; Ding L; Liang J; Chen J; Tang Y; Xue H; Gu L; Shen S; Li B; Chen J
Pediatr Blood Cancer; 2018 Oct; 65(10):e27266. PubMed ID: 29943896
[TBL] [Abstract][Full Text] [Related]
17. The distribution of MLL breakpoints correlates with outcome in infant acute leukaemia.
Emerenciano M; Meyer C; Mansur MB; Marschalek R; Pombo-de-Oliveira MS;
Br J Haematol; 2013 Apr; 161(2):224-36. PubMed ID: 23432364
[TBL] [Abstract][Full Text] [Related]
18. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96).
Isoyama K; Eguchi M; Hibi S; Kinukawa N; Ohkawa H; Kawasaki H; Kosaka Y; Oda T; Oda M; Okamura T; Nishimura S; Hayashi Y; Mori T; Imaizumi M; Mizutani S; Tsukimoto I; Kamada N; Ishii E
Br J Haematol; 2002 Sep; 118(4):999-1010. PubMed ID: 12199778
[TBL] [Abstract][Full Text] [Related]
19. Suppression of the let-7b microRNA pathway by DNA hypermethylation in infant acute lymphoblastic leukemia with MLL gene rearrangements.
Nishi M; Eguchi-Ishimae M; Wu Z; Gao W; Iwabuki H; Kawakami S; Tauchi H; Inukai T; Sugita K; Hamasaki Y; Ishii E; Eguchi M
Leukemia; 2013 Feb; 27(2):389-97. PubMed ID: 22918121
[TBL] [Abstract][Full Text] [Related]
20. Subclonality and prenatal origin of RAS mutations in KMT2A (MLL)-rearranged infant acute lymphoblastic leukaemia.
Emerenciano M; Barbosa Tda C; de Almeida Lopes B; Meyer C; Marschalek R; Pombo-de-Oliveira MS
Br J Haematol; 2015 Jul; 170(2):268-71. PubMed ID: 25613690
[No Abstract] [Full Text] [Related]
[Next] [New Search]
